Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma

5 Mar 2013

Abstract excerpt

PURPOSE: Persistently elevated posttreatment plasma EBV DNA is a robust predictor of relapse in nasopharyngeal carcinoma (NPC). However, assay standardization is necessary for use in biomarker-driven trials. We conducted a study to harmonize the method between four centers with expertise in EBV DNA quantitation. EXPERIMENTAL DESIGN: Plasma samples of 40 patients with NPC were distributed to four centers. DNA was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Head and Neck Cancer Studies
Share to Salivary Gland Disorders and Functions
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23459720
DOI: 10.1158/1078-0432.ccr-12-3702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal CarcinomaPMID 23459720Read ↗

Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal CancerSemantic proximity Read ↗

Comparison of Real-Time PCR and Digital PCR for Detection of Plasma Epstein-Barr Virus DNA in Nasopharyngeal CarcinomaSemantic proximity Read ↗

Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal CarcinomaSemantic proximity Read ↗

Multicenter Comparison of Different Real-Time PCR Assays for Quantitative Detection of Epstein-Barr VirusSemantic proximity Read ↗

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasmaSemantic proximity Read ↗

Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinomaSemantic proximity Read ↗

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal CarcinomaSemantic proximity Read ↗

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinomaSemantic proximity Read ↗

Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinomaSemantic proximity Read ↗

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.